Business Wire

Huawei at MWC 2023: Intelligent World Needs Stronger ICT Industry and Digital Economy

Share

During MWC Barcelona 2023, Huawei will be meeting with operators, industry partners, and other key opinion leaders from around the world to discuss "GUIDE to the Intelligent World". Together, they will look at how to use the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity in an intelligent world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006057/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Huawei's Hall 1 exhibition booth at MWC Barcelona 2023 (Photo: Huawei)

Huawei’s main exhibition booth in MWC Barcelona's Hall 1 is designed around the concept of “Intelligent Future, Full of Hope”. At the booth, Huawei painted a picture of an era fueled by the digital economy and defined by collaboration that is more vibrant and full of unlimited possibilities. At the event, Huawei is also showcasing its latest products and solutions that deliver ultimate 5G experiences, premium and intelligent ultra-broadband connectivity, digital and intelligent transformation, and their Green 1-2-3 solution. Huawei's offerings show a clear commitment to innovating for the 5.5G era, creating value for customers, and stimulating the digital economy.

By the end of 2022, 5G had already proven to be a global commercial success, with over a billion mobile users connecting with 5G. Leading operators in China, South Korea, Switzerland, Finland, and Kuwait have already achieved 5G user penetration rates of more than 30%, and more than 30% of their traffic comes from 5G.

According to Ookla's latest 5G City Benchmark Report, Huawei has played an important part in 5G network construction in all of the top 10 cities among the world's 40 representative 5G-enabled cities. It's important to note that 5G performance results in these 10 cities show that the 5G networks constructed by Huawei offer the best experience.

Following on from Huawei's concept of "Striding Towards the 5.5G Era" that was proposed in July 2022, Huawei is highlighting the five major characteristics of the 5.5G era: 10 Gbps experiences, full-scenario interconnection, integrated sensing and communication, L4 autonomous driving networks, and green ICT. Leading global operators, standards organizations, and industry ecosystem partners are coming together to promote innovation and exploration for this 5.5G era, as it will create more new applications and business opportunities.

Ongoing and robust investment into ICT infrastructure directly spurs growth within the digital economy. A third-party report shows that, as new networks evolve from one generation to another, this effect will be further amplified by 15%. Looking towards the future, we believe the GUIDE business blueprint that combines both 5G and 5.5G clearly lays out how ICT evolution will progress and bring about greater value.

Together with our customers and partners, we will continue to innovate, building intelligent connectivity and redefining computing. This collaboration on innovation will create even greater value for the ICT industry and make the industry as a whole more resilient and prosperous.

Huawei’s Enterprise division is also hosting their own event at MWC 2023, themed “Leading Digital Infrastructure for New Value Together”, where they will launch more than 50 innovative products and solutions for global customers. Highlights here include their Intelligent Simplified Campus Network Solution, a series of innovative data center solutions, and business strategies for small- and medium-sized enterprises (SMEs).

In the device field, Huawei is showcasing their new HUAWEI Mate 50 series, HUAWEI WATCH Buds, HUAWEI WATCH GT Cyber, that come packed with new innovation in areas like mobile imaging, fitness and health, and smart office.

MWC Barcelona 2023 runs from February 27 to March 2 in Barcelona, Spain. Huawei showcases its products and solutions at stand 1H50 in Fira Gran Via Hall 1. Together with global operators, industry professionals, and opinion leaders, we dive into topics such as 5G business success, 5.5G opportunities, green development, digital transformation, and our vision of using the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity. For more information, please visit: https://carrier.huawei.com/en/events/mwc2023.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Olivia Zhang
+86-15013066795 / +44-7444720703
zhangningning7@huawei.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye